Description: Morphic Holding, Inc., a biopharmaceutical company, focuses on the discovery and development of oral small-molecule integrin therapeutics. The company's lead product candidates in clinical development are MORF-720, a selective oral avb6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis; and a4b7 specific integrin inhibitors for the treatment of inflammatory bowel disease. Its product candidates in discovery stage include an avb1 integrin for the treatment of fibrosis; two TGF-b activations for gastrointestinal cancers and fibrosis; and other aI domain integrins. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.
Home Page: www.morphictx.com
MORF Technical Analysis
35 Gatehouse Drive, A2
Waltham,
MA
02451
United States
Phone:
781 996 0955
Officers
| Name | Title |
|---|---|
| Dr. Praveen P. Tipirneni M.D. | CEO, MD & Director |
| Dr. Bruce N. Rogers Ph.D. | Pres |
| Dr. Timothy A. Springer Ph.D. | Founder, Independent Director & Member of Scientific Advisory Board |
| Dr. Marc Schegerin M.B.A., M.D. | CFO & COO |
| Mr. William D. DeVaul Esq. | Gen. Counsel & Sec. |
| Mr. Robert E. Farrell Jr., CPA, CPA | Sr. VP of Fin. & Operations and Chief Accounting Officer |
| Dr. Blaise Lippa Ph.D. | Chief Scientific Officer |
| Mr. Aaron Pelta | Sr. VP of Bus. & Corp. Devel. |
| Ms. Joanne Gibbons | Sr. VP of Regulatory Affairs |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.901 |
| Price-to-Sales TTM: | 14.0334 |
| IPO Date: | 2019-06-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 103 |